Skip to main content
Erschienen in: The European Journal of Health Economics 3/2008

01.08.2008 | Original paper

Preferences and utilities for the symptoms of moderate to severe allergic asthma

verfasst von: Andrew Lloyd, Scott Doyle, Sarah Dewilde, Florian Turk

Erschienen in: The European Journal of Health Economics | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Patients with moderate to severe allergic asthma have persistent poorly controlled asthma despite inhaled or systemic corticosteroid therapy. New therapies are becoming more widely available to treat such patients, but their value needs to be formally assessed in an economic evaluation. Within a publicly funded health care system such an analysis should reflect societal preferences when measuring treatment benefits. The aim of this study was to elicit societal preferences for the symptom burden associated with moderate to severe allergic asthma.

Method

Existing daily symptom diary data from a clinical trial were used to develop health state descriptions for evaluation in a standard gamble interview. Five health states were produced that reflected five distinct levels of control ranging from ‘complete control of asthma’ to ‘worsening of asthma’, as defined by another outcome measure. The symptom diary data were also used as attributes in a discrete choice experiment (DCE) to estimate willingness to pay for improvements in symptoms. Members of the general public (n = 101) completed the interview.

Results

Thirteen participants failed the consistency checks and were excluded from the analysis. Societal utility ratings for the health states ranged from 0.71 (worsening of asthma) to 0.78 (complete control of asthma). The participants were also willing to pay £160 a month for the avoidance of all symptoms.

Conclusions

The range of utility values (0.71–0.78) demonstrates the severity of moderate to severe allergic asthma. However the spread of scores between complete control of asthma and worsening of asthma was lower than was expected. The community sample placed only a moderate value on the avoidance of all asthma symptoms in the DCE survey. The results suggest that the community sample may not have fully understood the benefits of control over asthma symptoms and the limitations such symptoms can impose on everyday life.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bennett, K., Torrance, G.: Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques. In: Spilker, B. (eds.) HRQL and Pharmacoeconomics in Clinical Trials, 2nd edn. Lippincott-Raven, Philadelphia, pp. 253–266 (1996) Bennett, K., Torrance, G.: Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques. In: Spilker, B. (eds.) HRQL and Pharmacoeconomics in Clinical Trials, 2nd edn. Lippincott-Raven, Philadelphia, pp. 253–266 (1996)
2.
Zurück zum Zitat Busse, W., Corren, J., Quentin Lanier, B., McAlary, M., Fowler-Taylor, A., Della Cioppa, van As A., Gupta, N.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184–190 (2001)CrossRef Busse, W., Corren, J., Quentin Lanier, B., McAlary, M., Fowler-Taylor, A., Della Cioppa, van As A., Gupta, N.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184–190 (2001)CrossRef
3.
Zurück zum Zitat Conner-Spady, B.L., et al.: A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant. 36(3), 251–259 (2005)CrossRef Conner-Spady, B.L., et al.: A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant. 36(3), 251–259 (2005)CrossRef
4.
Zurück zum Zitat Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., Fowler-Taylor, A., Liu, J., Gupta, N.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. 111, 278–284 (2003)CrossRef Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., Fowler-Taylor, A., Liu, J., Gupta, N.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. 111, 278–284 (2003)CrossRef
5.
Zurück zum Zitat Furlong, W., Feeny, D., Torrance, G.W., Barr, R.D., Horsman, J.: Guide to design and development of health-state utility instrumentation. McMaster University CHEPA working paper series (1990) Furlong, W., Feeny, D., Torrance, G.W., Barr, R.D., Horsman, J.: Guide to design and development of health-state utility instrumentation. McMaster University CHEPA working paper series (1990)
6.
Zurück zum Zitat Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January 1995 (updated 2002, 2003; accessed 26 Oct 2004). Available at: http://www.ginasthma.com Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January 1995 (updated 2002, 2003; accessed 26 Oct 2004). Available at: http://​www.​ginasthma.​com
7.
Zurück zum Zitat Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, MC.: Cost-Effectiveness in Health and Medicine. Oxford University Press (1996) Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, MC.: Cost-Effectiveness in Health and Medicine. Oxford University Press (1996)
8.
Zurück zum Zitat Greene, W.H., Greene, L.K., Seaks, T.G.: Estimating the functional form of the independent variables in probit models. Appl. Econ. 27, 193–196 (1995)CrossRef Greene, W.H., Greene, L.K., Seaks, T.G.: Estimating the functional form of the independent variables in probit models. Appl. Econ. 27, 193–196 (1995)CrossRef
9.
Zurück zum Zitat Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hebert, J., Bousquet, J., Beech, K-M., Ramos, S., Canonica, G.W., Hedgecock, S., Fox, H., Blogg, M., Surrey, K.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Asthma 10, 1398 (2004) Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hebert, J., Bousquet, J., Beech, K-M., Ramos, S., Canonica, G.W., Hedgecock, S., Fox, H., Blogg, M., Surrey, K.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Asthma 10, 1398 (2004)
10.
Zurück zum Zitat Kind, P., Dolan, P., Gudex, C., Williams, A.: Variations in population health status: results from a United Kingdom national questionnaire survey. Br. Med. J. 316, 736–741 (1998) Kind, P., Dolan, P., Gudex, C., Williams, A.: Variations in population health status: results from a United Kingdom national questionnaire survey. Br. Med. J. 316, 736–741 (1998)
11.
Zurück zum Zitat Lloyd, A.J., McIntosh, E., Rabe, K., Williams, A.E.: Patient preferences for asthma therapy: a discrete choice experiment. Prim. Care Respir. J. (in press) Lloyd, A.J., McIntosh, E., Rabe, K., Williams, A.E.: Patient preferences for asthma therapy: a discrete choice experiment. Prim. Care Respir. J. (in press)
12.
Zurück zum Zitat Lloyd, A.J., Price, D., Brown, R.: The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim. Care Respir. J. 16, 22–27 (2007)CrossRef Lloyd, A.J., Price, D., Brown, R.: The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim. Care Respir. J. 16, 22–27 (2007)CrossRef
13.
Zurück zum Zitat Lloyd, A., Turk, F., Leighton, T., Canonica, G.W.: Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J. Med. Econ. 10(3), 285–296 (2007)CrossRef Lloyd, A., Turk, F., Leighton, T., Canonica, G.W.: Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J. Med. Econ. 10(3), 285–296 (2007)CrossRef
14.
Zurück zum Zitat Louviere, J., Hensher, D., Swait, J.: Conjoint preference elicitation methods in the broader context of Random Utility Theory preference eliciation methods. In: Gustafson, A., Hermann, A., Huber, F. (eds.) Conjoint Measurement: Methods and Applications. Springer, Berlin, pp. 305–344 (2001) Louviere, J., Hensher, D., Swait, J.: Conjoint preference elicitation methods in the broader context of Random Utility Theory preference eliciation methods. In: Gustafson, A., Hermann, A., Huber, F. (eds.) Conjoint Measurement: Methods and Applications. Springer, Berlin, pp. 305–344 (2001)
15.
Zurück zum Zitat Manski, C.F.: The structure of random utility models. Theory Decis. 8(229), 254 (1977) Manski, C.F.: The structure of random utility models. Theory Decis. 8(229), 254 (1977)
16.
Zurück zum Zitat Marshall. G.D. Jr, Sorkness, C.A.: IgE-blocking therapy for difficult-to-treat asthma: a brief review. Manag. Care 13(3), 45–50 (2004) Marshall. G.D. Jr, Sorkness, C.A.: IgE-blocking therapy for difficult-to-treat asthma: a brief review. Manag. Care 13(3), 45–50 (2004)
17.
Zurück zum Zitat McFadden, E.R. Jr: Acute severe asthma. Am. J. Respir. Crit. Care Med. 168(7), 740–759 (2003)CrossRef McFadden, E.R. Jr: Acute severe asthma. Am. J. Respir. Crit. Care Med. 168(7), 740–759 (2003)CrossRef
18.
Zurück zum Zitat Norum, J., et al.: Treatment costs in Hodgkin’s disease: a cost-utility analysis. Eur. J. Cancer 32A(9), 1510–1517 (1996)CrossRef Norum, J., et al.: Treatment costs in Hodgkin’s disease: a cost-utility analysis. Eur. J. Cancer 32A(9), 1510–1517 (1996)CrossRef
20.
Zurück zum Zitat Osman, L.M., McKenzie, L., Cairns, J., Friend, J.A.R., Godden, D.J., Legge, J.S., Douglas, J.G.: Patient weighting of importance of asthma symptoms. Thorax 56, 138–142 (2001)CrossRef Osman, L.M., McKenzie, L., Cairns, J., Friend, J.A.R., Godden, D.J., Legge, J.S., Douglas, J.G.: Patient weighting of importance of asthma symptoms. Thorax 56, 138–142 (2001)CrossRef
21.
Zurück zum Zitat Roe, B., Boyle, K.J., Teisl, M.F.: Using conjoint analysis to derive estimates of compensating variation. J. Environ. Econ. Manage. 31, 145–159 (1996)CrossRef Roe, B., Boyle, K.J., Teisl, M.F.: Using conjoint analysis to derive estimates of compensating variation. J. Environ. Econ. Manage. 31, 145–159 (1996)CrossRef
22.
Zurück zum Zitat Solèr, M., Matz, J., Townley, R., Buhl, R., O’Brien J., Fox, H., Thirlwell, J., Gupta, N.,Della Cioppa, G.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254–261 (2001)CrossRef Solèr, M., Matz, J., Townley, R., Buhl, R., O’Brien J., Fox, H., Thirlwell, J., Gupta, N.,Della Cioppa, G.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254–261 (2001)CrossRef
23.
Zurück zum Zitat Torrance, G.W.: Measurement of health state utilities for economic appraisal. J. Health Econ. 5(1), 1–30 (1986)CrossRef Torrance, G.W.: Measurement of health state utilities for economic appraisal. J. Health Econ. 5(1), 1–30 (1986)CrossRef
24.
Zurück zum Zitat Torrance, G.W.: Preferences for health states: a review of measurement methods. Clin. Econ. Eval. Perinat. Dev. Med. 20, 37–45 (1982) Torrance, G.W.: Preferences for health states: a review of measurement methods. Clin. Econ. Eval. Perinat. Dev. Med. 20, 37–45 (1982)
25.
Zurück zum Zitat Torrance, G.W.: Utility approach to measuring health-related quality of life. J. Chronic Dis. 40(6), 593–600 (1987)CrossRef Torrance, G.W.: Utility approach to measuring health-related quality of life. J. Chronic Dis. 40(6), 593–600 (1987)CrossRef
Metadaten
Titel
Preferences and utilities for the symptoms of moderate to severe allergic asthma
verfasst von
Andrew Lloyd
Scott Doyle
Sarah Dewilde
Florian Turk
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 3/2008
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-007-0075-0

Weitere Artikel der Ausgabe 3/2008

The European Journal of Health Economics 3/2008 Zur Ausgabe